@Article{info:doi/10.2196/jmir.6303,
author="Innominato, Pasquale F
and Komarzynski, Sandra
and Mohammad-Djafari, Ali
and Arbaud, Alexandre
and Ulusakarya, Ayhan
and Bouchahda, Mohamed
and Haydar, Mazen
and Bossevot-Desmaris, Rachel
and Plessis, Virginie
and Mocquery, Magali
and Bouchoucha, Davina
and Afshar, Mehran
and Beau, Jacques
and Karabou{\'e}, Abdoulaye
and Mor{\`e}re, Jean-Fran{\c{c}}ois
and Fursse, Joanna
and Rovira Simon, Jordi
and Levi, Francis",
title="Clinical Relevance of the First Domomedicine Platform Securing Multidrug Chronotherapy Delivery in Metastatic Cancer Patients at Home: The inCASA European Project",
journal="J Med Internet Res",
year="2016",
month="Nov",
day="25",
volume="18",
number="11",
pages="e305",
keywords="domomedicine; chronotherapy; actigraphy; MDASI; telemonitoring",
abstract="Background: Telehealth solutions can improve the safety of ambulatory chemotherapy, contributing to the maintenance of patients at their home, hence improving their well-being, all the while reducing health care costs. There is, however, need for a practicable multilevel monitoring solution, encompassing relevant outputs involved in the pathophysiology of chemotherapy-induced toxicity. Domomedicine embraces the delivery of complex care and medical procedures at the patient's home based on modern technologies, and thus it offers an integrated approach for increasing the safety of cancer patients on chemotherapy. Objective: The objective was to evaluate patient compliance and clinical relevance of a novel integrated multiparametric telemonitoring domomedicine platform in cancer patients receiving multidrug chemotherapy at home. Methods: Self-measured body weight, self-rated symptoms using the 19-item MD Anderson Symptom Inventory (MDASI), and circadian rest-activity rhythm recording with a wrist accelerometer (actigraph) were transmitted daily by patients to a server via the Internet, using a dedicated platform installed at home. Daily body weight changes, individual MDASI scores, and relative percentage of activity in-bed versus out-of-bed (I<O) were computed. Chemotherapy was administered according to the patient medical condition. Compliance was evaluated according to the proportions of (1) patient-days with all data available (full) and (2) patient-days with at least one parameter available (minimal). Acceptability was assessed using the Whole Systems Demonstrator Service User Technology Acceptability Questionnaire. Linear discriminant analysis was used to identify the combination of parameters associated with subsequent unplanned hospitalization. Results: A total of 31 patients (males: 55{\%} [17/31]; World Health Organization Performance Status=0: 29{\%} (9/31); age range: 35-91 years) participated for a median of 58 days (38-313). They received a total of 102 chemotherapy courses (64.7{\%} as outpatients). Overall full compliance was 59.7{\%} (522/874), with at least one data available for 830/874 patient-days (95.0{\%}), during the 30-day per-protocol span. Missing data rates were similar for each parameter. Patients were altogether satisfied with the use of the platform. Ten toxicity-related hospitalizations occurred in 6 patients. The combination of weighted circadian function (actigraphy parameter I<O), body weight change, and MDASI scores predicted for ensuing emergency hospitalization within 3 days, with an accuracy of 94{\%}. Conclusions: Multidimensional daily telemonitoring of body weight, circadian rest-activity rhythm, and patient-reported symptoms was feasible, satisfactory, and clinically relevant in patients on chemotherapy. This domomedicine platform constitutes a unique tool for the further development of safe home-based chemotherapy administration. ",
issn="1438-8871",
doi="10.2196/jmir.6303",
url="http://www.jmir.org/2016/11/e305/",
url="https://doi.org/10.2196/jmir.6303",
url="http://www.ncbi.nlm.nih.gov/pubmed/27888171"
}